Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 and Enzalutamide in Progressive Metastatic Castrate-Resistant Prostate Cancer
NCT02225704Phase 2Completed
- Sponsor
- Cancer Trials Ireland
- Start
- Jun 2015
- Primary completion
- Jul 2017
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
A Phase 2 trial of radium-223 dichloride in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Cancer Trials Ireland. Started Jun 2015; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02225704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02225704.